Compare American Tower Corp (AMT) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Cytokinetics Inc — how do they compare? American Tower Corp trades at $171 (market cap $79.00B), while Cytokinetics Inc trades at $76.43 (market cap $10.63B). The key difference: American Tower Corp is far larger — about 7.4× Cytokinetics Inc's market cap, and American Tower Corp pays a 4.12% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AMT | CYTK | |
|---|---|---|
Market Cap | $79.00B | $10.63B |
Sector | Real Estate | Technology |
52-Week High | $211.88 | $87.26 |
52-Week Low | $162.11 | $34.31 |
Enterprise Value | $122.53B | $10.74B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower Corporation (AMT) trades at $171.4, up 1.35% over the past 24 hours, with a bearish technical signal from moving averages but strong fundamental performance. The company reported Q2 2026 earnings beats, with EPS of $1.86 versus $1.57 expected, and maintains robust profitability margins, including a net income margin of 26.81%. Recent news highlights accelerated lease contract growth and a positive analyst consensus.
The outlook for AMT is supported by solid earnings growth and a 27.3% upside to the consensus price target of $206.17, though risks include interest rate sensitivity and high debt levels. Investment appeal hinges on execution in telecom infrastructure and data center expansion, balanced against macroeconomic pressures.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
